CompletedNot Applicable

Transcriptomic Evaluation of Endometrial Receptivity

United States63 participantsStarted 2020-01-28

Plain-language summary

The purpose of this study is to comprehensively evaluate the transcriptomic signal of the endometrium before, during, and after the window of receptivity.

Who can participate

Age range18 Years – 50 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Regular menstrual cycles
✓. Age 18-50
✓. Normal baseline ultrasound
✓. No intrauterine procedures in prior 90 days

Exclusion criteria

✕. Any contraindications to undergoing estrogen stimulation of the endometrium
✕. Current smoking status
✕. Multiple risk factors for arterial cardiovascular disease (smoking, diabetes, and hypertension)
✕. Hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg)
✕. Venous thromboembolism (current or history of)
✕. Known thrombogenic mutations
✕. Known ischemic heart disease
✕. History of stroke

What they're measuring

transcriptomic evaluation

Timeframe: 90 days

Trial details

NCT IDNCT04141085

SponsorReproductive Medicine Associates of New Jersey

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-01-31

View on ClinicalTrials.gov More Infertility, Female trials